Romano Kathryn's Form 4 filing
Krystal Biotech, Inc. (KRYS) · filed Mar 3, 2026
- Accession no.
- 0001801385-26-000002
- Filed
- Mar 3, 2026
- Trade date
- Feb 27-Mar 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $200.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Romano KathrynCIK 0001801385 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | MOption exerciseAcquired | +7,500 | $0.00 | $0 | 26,068 | Direct | |
| Feb 27, 2026 | Common Stock | FTax withholdingDisposed | −3,262 | $275.64 | −$899,137.68 | 22,806 | Direct | |
| Feb 27, 2026 | Common Stock | MOption exerciseAcquired | +550 | $0.00 | $0 | 23,356 | Direct | |
| Feb 27, 2026 | Common Stock | FTax withholdingDisposed | −240 | $275.64 | −$66,153.6 | 23,116 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −750 | $267.60 | −$200,700 | 22,366 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 0 | Direct | |
| Feb 27, 2026 | Common Stock | MOption exerciseDisposed | −550 | $0.00 | $0 | 1,650 | Direct | |
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +13,575 | $0.00 | $0 | 13,575 | Direct | |
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +5,442 | $0.00 | $0 | 5,442 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.